AbbVie Inc. (ABBV) Purchased 1/11/2016

About a year ago today, I was a little over a quarter of the way through my purchases of 42 stocks to comprise my "nonPension".  All of the my choices seemed undervalued at the time.  Most of my choices had a significant track record of raising dividends regularly.  Some of those choices ended up disappointing me in some ways, while others performed very well.

Abbvie Inc. (ABBV) has done nothing but impress me so far.  After a couple of years of being overvalued, ABBV pulled back from its 2014 and 2015 peaks, and was comfortably in the "green zone" by early 2016.  I jumped at the opportunity to buy some ABBV, which I had avoided at the higher prices earlier.

Throughout 2016, the price of ABBV moved up and down, remaining in undervalued territory, even as profits rose.  Now estimates for 2017-2019 seem to indicate that profits might continue to rise, and the price seems to remain fairly low for now.  As a result, ABBV remains an attractive buy, and I have recently added more shares of ABBV to a different brokerage account.

How has ABBV performed over the past 12 months?   Double-digit price growth and double-digit dividend growth:

As a bonus, ABBV has a relatively high dividend yield when compared to most of my other holdings.  When I first purchased ABBV, my monthly average for dividend payments going forward was $1.71.  Thanks to the dividend increase and dividend reinvestment, my monthly payment average is an even stronger $1.99.  If this kind of growth continues, then ABBV will contribute more than its fair share of income to my nonPension.